|Videos|July 13, 2023
THOR: Erdafitinib vs Chemotherapy in Metastatic Urothelial Cancer with FGFR Alterations
Expert oncologists offer insights on recent data from the THOR trial, which compared erdafitinib with chemotherapy in patients with metastatic bladder cancer.
Advertisement
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5